This study is a multi-center, open/unblended study (3:1Treatment: Control) to evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and exercise control only. Mean % Total Body Weight Loss \[TBWL\] in Treatment subjects versus that of Control subjects at 12 months is the primary endpoint. The proportion of subjects achieving ≥ 5% TBWL at 12 months in the treatment group is a co-primary endpoint.
This study will evaluate the safety and effectiveness of the g-Cath EZ Suture Anchor Delivery Catheter as an early weight loss intervention compared to a diet and exercise control only. The weight loss outcomes will be used to assess treatment effect. This study is a multi-center, open/unblinded, prospective randomized feasibility study (3:1Treatment: Control) study. Patients in the control group will be offered the opportunity to crossover to the treatment group at 12 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
Krakenhaus Hallein
Hallein, Salzburg, Austria
Atrium Medical Centre
Heerlen, Netherlands
Centro Medico Teknon
Barcelona, Spain
Primary Safety Endpoint
Incidence and severity of Adverse Events \[AE\] over 12 Months
Time frame: 12 months
Primary Efficacy Endpoint
Mean % TBWL at 12 months for Treatment subjects compared to Control subjects
Time frame: 12 months
Co-Primary Efficacy Endpoint
The proportion of Treatment subjects achieving ≥ 5% TBWL at 12 months
Time frame: 12 months
First Secondary Efficacy Endpoint
Mean % TBWL at 24 months.
Time frame: 24 months
Second Secondary Efficacy endpoint
Proportion of subjects achieving ≥ 5% TBWL at 24 months
Time frame: 24 months
Third Secondary Efficacy endpoint
Satiety changes (volume and time to satiety at 2, 6, 12 months post-procedure)
Time frame: 2, 6, 12 months
Fourth Secondary Efficacy endpoint
% Estimated Weight Loss \[EWL\] at 12 months and 18 months \[% EWL will be calculated using BMI-25 criteria\]
Time frame: 12 & 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.